Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAURIEL: Semorinemab in Prodromal to Mild Alzheimer's Disease
NCT03289143Phase 2Terminated
- Sponsor
- Genentech
- Start
- Oct 2017
- Primary completion
- Jan 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of semorinemab in Alzheimer's disease (AD) (4 arms), sponsored by Genentech. Primary endpoints: Clinical Dementia Rating-Sum of Boxes at 73 Weeks, Percentage of Participants With Adverse Events up to 39 months and 2 more. Started Oct 2017; status: terminated.
02
Drugs
semorinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03289143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03289143.